The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group Holding Ltd. (BABA), ...

The stock price of the two most prominent players in the diabetes and obesity care market, Novo Nordisk NVO and Eli Lilly LLY ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks ...

Developed initially to manage diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have skyrocketed in popularity ...

Novo Nordisk shares jump close to 14% on promising trial results for amycretin, a once-weekly obesity drug, signaling fierce ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

Lilly is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s. However, sales of Mounjaro/Zepbound were disappointing in the second half of 2024 due to slower-than ...